The Beauty Health Company Statistics
Total Valuation
SKIN has a market cap or net worth of $118.51 million. The enterprise value is $266.59 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SKIN has 127.77 million shares outstanding. The number of shares has decreased by -4.70% in one year.
| Current Share Class | 127.77M |
| Shares Outstanding | 127.77M |
| Shares Change (YoY) | -4.70% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 9.05% |
| Owned by Institutions (%) | 64.14% |
| Float | 82.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 38.86 |
| PS Ratio | 0.39 |
| Forward PS | 0.39 |
| PB Ratio | 1.94 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.19 |
| P/OCF Ratio | 3.16 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 58.64, with an EV/FCF ratio of 7.17.
| EV / Earnings | n/a |
| EV / Sales | 0.89 |
| EV / EBITDA | 58.64 |
| EV / EBIT | n/a |
| EV / FCF | 7.17 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 6.20.
| Current Ratio | 1.66 |
| Quick Ratio | 1.36 |
| Debt / Equity | 6.20 |
| Debt / EBITDA | 38.08 |
| Debt / FCF | 10.19 |
| Interest Coverage | -1.08 |
Financial Efficiency
Return on equity (ROE) is -16.87% and return on invested capital (ROIC) is -9.53%.
| Return on Equity (ROE) | -16.87% |
| Return on Assets (ROA) | -2.19% |
| Return on Invested Capital (ROIC) | -9.53% |
| Return on Capital Employed (ROCE) | -6.64% |
| Weighted Average Cost of Capital (WACC) | 5.67% |
| Revenue Per Employee | $490,685 |
| Profits Per Employee | -$15,529 |
| Employee Count | 613 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.78 |
Taxes
In the past 12 months, SKIN has paid $3.58 million in taxes.
| Income Tax | 3.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.78% in the last 52 weeks. The beta is 1.21, so SKIN's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -30.78% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 40.43 |
| Average Volume (20 Days) | 771,965 |
Short Selling Information
The latest short interest is 15.34 million, so 12.01% of the outstanding shares have been sold short.
| Short Interest | 15.34M |
| Short Previous Month | 15.65M |
| Short % of Shares Out | 12.01% |
| Short % of Float | 18.52% |
| Short Ratio (days to cover) | 17.44 |
Income Statement
In the last 12 months, SKIN had revenue of $300.79 million and -$9.52 million in losses. Loss per share was -$0.16.
| Revenue | 300.79M |
| Gross Profit | 196.36M |
| Operating Income | -20.80M |
| Pretax Income | -5.94M |
| Net Income | -9.52M |
| EBITDA | 4.55M |
| EBIT | -20.80M |
| Loss Per Share | -$0.16 |
Full Income StatementBalance Sheet
The company has $230.67 million in cash and $378.76 million in debt, with a net cash position of -$148.08 million or -$1.16 per share.
| Cash & Cash Equivalents | 230.67M |
| Total Debt | 378.76M |
| Net Cash | -148.08M |
| Net Cash Per Share | -$1.16 |
| Equity (Book Value) | 61.06M |
| Book Value Per Share | 0.48 |
| Working Capital | 123.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $37.49 million and capital expenditures -$303,000, giving a free cash flow of $37.18 million.
| Operating Cash Flow | 37.49M |
| Capital Expenditures | -303,000 |
| Depreciation & Amortization | 25.35M |
| Net Borrowing | -173.35M |
| Free Cash Flow | 37.18M |
| FCF Per Share | $0.29 |
Full Cash Flow StatementMargins
Gross margin is 65.28%, with operating and profit margins of -6.92% and -3.16%.
| Gross Margin | 65.28% |
| Operating Margin | -6.92% |
| Pretax Margin | -1.97% |
| Profit Margin | -3.16% |
| EBITDA Margin | 1.51% |
| EBIT Margin | -6.92% |
| FCF Margin | 12.36% |
Dividends & Yields
SKIN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.70% |
| Shareholder Yield | 4.70% |
| Earnings Yield | -8.03% |
| FCF Yield | 31.37% |
Analyst Forecast
The average price target for SKIN is $2.03, which is 118.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.03 |
| Price Target Difference | 118.87% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SKIN has an Altman Z-Score of -0.41 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.41 |
| Piotroski F-Score | 5 |
